Sustainability Report

Overview

The report presents Lumosa Therapeutics' inaugural sustainability disclosure for 2024, covering governance, climate risk, environmental management, workforce practices, and social engagement. The company set an average 3% GHG emissions reduction target for 2028 against a 2023 baseline and reports TCFD adoption. Its 2024 energy consumption was 323.917 GJ and entirely non-renewable purchased electricity. The company also reports 32 year-end employees and zero occupational injuries, fires, or illnesses.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services